tradingkey.logo
tradingkey.logo
Search

Athyrium Capital Management And Esperion Enter Into $50 Million Japan Royalty Financing To Support Strategic Acquisition Of Corstasis Therapeutics

ReutersApr 2, 2026 9:37 PM

- Esperion Therapeutics Inc ESPR.O:

  • ATHYRIUM CAPITAL MANAGEMENT AND ESPERION ENTER INTO $50 MILLION JAPAN ROYALTY FINANCING TO SUPPORT STRATEGIC ACQUISITION OF CORSTASIS THERAPEUTICS

  • ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO RECEIVE TIERED ROYALTIES OF 12%-33% AND MILESTONE PAYMENTS UNTIL 2.0X INVESTMENT

  • ESPERION THERAPEUTICS INC - FINANCING SUPPORTS ESPERION'S ACQUISITION OF CORSTASIS THERAPEUTICS, DEVELOPER OF ENBUMYST

  • ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO BUY 100% OF ESPERION'S ROYALTY INTEREST ON OTSUKA'S JAPAN SALES FROM JAN 1, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI